Sydenham RV, Jarbol DE, Hansen MP, Justesen US, Watson V, Pedersen LB. Prescribing antibiotics: factors driving decision-making in general practice. A discrete choice experiment. Soc Sci Med. 2022 Jul;305:115033. doi: 10.1016/j.socscimed.2022.115033
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Dickey H, Ikenwilo D, Norwood P, Watson V, Zangelidis A. "Doctor my eyes": a natural experiment on the demand for eye care services. Soc Sci Med. 2016 Feb;150:117-27. doi: 10.1016/j.socscimed.2015.12.037
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Poulos C, Yang JC, Patil SR, Pattanayak S, Wood S, Goodyear L, Gonzalez JM. Consumer preferences for household water treatment products in Andhra Pradesh, India. Soc Sci Med. 2012 Aug 1;75(4):738-46.
Bernfort L, Brodtkorb T. QALY som effektmått inom vården : möjligheter och begränsningar. Linköping: linköping University Electronic Press. Cmt- Rapport. 2012.
Poulos C, Yang JC, Levin C, Minh HV, Giang KB, Nguyen D. Mothers' preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam. Soc Sci Med. 2011 Jul 1;73(2):226-34.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.
Brodtkorb T. National system for assessment, prioritization and introduction of non-pharmaceutical health technologies, a pilot study. Cmt- Rapport. 2010.
Novick D, Reed C, Gonzalez-Pinto A, Aguado J, Haro JM. Comparison of olanzapine and valproate over 12 months of treatment in the emblem study. J Psychopharmacol. 2010;24:A54.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. J Psychopharmacol. 2007;21(Suppl):A39.
Fireman B, Mines D, Lee J, Hunkeler EM. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Poster presented at the 2006 Summer Meeting of the British Association for Psychopharmacology; July 2006. Oxford, United Kingdom. [abstract] J Psychopharmacol. 2006 Sep; 20(5 Suppl):A58.
Aytac IA, Araujo AB, Johannes CB, Kleinman KP, McKinlay JB. Socioeconomic factors and incidence of erectile dysfunction: findings of the longitudinal Massachussetts Male Aging Study. Soc Sci Med. 2000 Sep 1;51(5):771-8.
Sloan FA, Whetten-Goldstien K, Gilsenan AW. Hospital pharmacy decisions: cost-containment, and use of cost-effectiveness analysis. Soc Sci Med. 1997 Aug;45(4):523-33.